|drug3548||Unfractionated heparin nebulized Wiki||1.00|
|drug4126||unfractionated Heparin Wiki||0.71|
|drug394||Bacille Calmette-Guérin (BCG) Wiki||0.71|
|D012141||Respiratory Tract Infections NIH||0.17|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
Hypercoagulability has been demonstrated in COVID-19, leading to respiratory distress and increased mortality. This is adaptive clinical trial to compare effectiveness and safety of four therapeutic strategies in hospital mortality in patients with COVID-19: standard prophylaxis, therapeutic dose anticoagulation, inhaled UFH associated with standard prophylaxis and ASA associated with standard prophylaxis.
Description: Number of COVID-19 positive patients who are alive within 30 days of symptoms onsetMeasure: Hospital discharge - alive / death Time: 30 days
Description: Comparison of length of mechanical ventilation free days between each treatment armMeasure: Length of mechanical ventilation free days Time: 30 days
Description: Comparison of length of renal replacement therapy free days between each treatment armMeasure: Length of renal replacement therapy free days Time: 30 days
Description: Comparison of number of thrombosis events between each treatment arm.Measure: Number of documented venous thromboembolism or arterial thrombosis Time: 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports